Patents Assigned to Genentech
  • Humanized anti-cmet antagonists
    Publication number: 20060134104
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: August 4, 2005
    Publication date: June 22, 2006
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Heregulin variants
    Patent number: 7063961
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-?1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: June 20, 2006
    Assignee: Genentech, Inc.
    Inventors: Marcus D. Ballinger, Jennifer T. Jones, Wayne J. Fairbrother, Mark X. Sliwkowski, James A. Wells
  • Bv8 nucleic acids and polypeptides with mitogenic activity
    Patent number: 7060278
    Abstract: The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer Le Couter
  • PRO1312 nucleic acids
    Patent number: 7060812
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Anti-VEGF antibodies
    Patent number: 7060269
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Protein formulation
    Patent number: 7060268
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Antibodies to heregulin 2
    Publication number: 20060122114
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Application
    Filed: September 12, 2005
    Publication date: June 8, 2006
    Applicant: Genentech, Inc.
    Inventors: Richard Vandlen, William Holmes
  • Thiocarbamate inhibitors of alpha-4 integrins
    Publication number: 20060122388
    Abstract: The invention provides novel thiocarbamate alpha-4 inhibitors of the general formula (I) that are resistant to metabolism having improved half-life and/or clearance properties compared to corresponding carbamate compounds wherein substituents L, X, Y, Z, R1-R4, m, n, o and p are as defined herein. Also provided are compositions comprising compounds of formula I and a carrier, diluent or excipient as well as methods of treating a disease or condition mediated by the binding interaction of alpha-4 integrins to its ligands such as inflammatory diseases.
    Type: Application
    Filed: January 11, 2006
    Publication date: June 8, 2006
    Applicant: Genentech, Inc.
    Inventor: David Jackson
  • VEGF-related protein
    Publication number: 20060121025
    Abstract: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.
    Type: Application
    Filed: February 3, 2006
    Publication date: June 8, 2006
    Applicant: Genentech, Inc.
    Inventors: James Lee, William Wood
  • Selecting patients for therapy with a her inhibitor
    Publication number: 20060121044
    Abstract: A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.
    Type: Application
    Filed: December 6, 2005
    Publication date: June 8, 2006
    Applicant: Genentech, Inc.
    Inventors: Lukas Amler, Thomas Januario
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7056736
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 6, 2006
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Ivar J. Kljavin, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Zemin Zhang
  • Pro 1474 polypeptides
    Patent number: 7057018
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: June 6, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Structured peptide scaffold for displaying turn libraries on phage
    Publication number: 20060110777
    Abstract: The invention is directed to a model system for structure-activity analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are combinatorial peptide libraries comprising disulfide-constrained cyclic peptides with sequences favorable for energy stabilized conformations. One aspect of the invention is directed to cyclic peptide scaffolds that present ?-hairpin structure in solution. Methods of selecting and using such peptide scaffolds are provided herein, which are useful for mimicking in vivo molecular interactions and designing therapeutic agents. Thus, the invention has profound utility for biological studies and drug development.
    Type: Application
    Filed: November 15, 2005
    Publication date: May 25, 2006
    Applicant: Genentech, Inc.
    Inventors: Andrea Cochran, Nicholas Skelton, Melissa Starovasnik
  • Human anti-factor IX/IXa antibodies
    Patent number: 7049411
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: May 23, 2006
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
  • Methods and deoxyribonucleic acid for the preparation of tissue factor protein
    Patent number: 7049131
    Abstract: DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: May 23, 2006
    Assignee: Genentech, Inc.
    Inventors: Richard M. Lawn, Gordon A. Vehar, Karen L. Wion
  • Process for protein extraction
    Publication number: 20060106205
    Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Application
    Filed: October 31, 2005
    Publication date: May 18, 2006
    Applicant: Genentech, Inc.
    Inventor: Richard Gehant
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7045603
    Abstract: The present invention is directed to novel polypeptide and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: May 16, 2006
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Treating a mammal with a formulation comprising an antibody which binds IgE
    Publication number: 20060099201
    Abstract: A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.
    Type: Application
    Filed: December 16, 2005
    Publication date: May 11, 2006
    Applicant: Genentech, Inc.
    Inventors: James Andya, Chung Hsu, Steven Shire, Sylvia Wu
  • Treating prostate cancer with anti-ErbB2 antibodies
    Patent number: 7041292
    Abstract: The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventor: Mark X. Sliwkowski
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7041805
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood